U.S. Markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.88+0.21 (+1.12%)
At close: 4:00PM EST

18.59 -0.29 (-1.54%)
After hours: 4:32PM EST

Sign in to post a message.
  • m
    I started following "lionstock-aletrs” (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • K
    MYGN has a mkt cap of only $1.2 B. It does the same type of tests as EXAS at $$18.7 B. What a joke!
  • j
    Ge general electric invented new breast test, machhine
  • A
    ALF Tanner
    Just read the quarterly report, and you will see that the current quarter is going to be a disaster:
    " During the last few weeks of March and into April, volumes for predominantly elective tests such as hereditary cancer, GeneSight, and Vectra declined approximately 70 to 75 percent, volumes for cancer tests such as Prolaris, EndoPredict, and myChoice HRD declined 40 to 45 percent, and volumes for our prenatal tests declined 20 to 25 percent."
  • s
    Morgan Stanley upgraded with $55 PT.
  • D
    Although I am angry at the results but I understand that compensation from insurance can be tricky. They have the products and they need to sell it better and make sure they get paid right for it. But after all what do you expect from a company who’s CEO named CAPONE 😂😂
  • g
    I have to agree with the representative from Cowen who, during the Q&A asked if a CEO change is enough. He suggested that the entire management team and Board needs to be looked at.
    I agree. They need to hire a seasoned no nonsense CEO who can quickly evaluate the existing management team and make significant changes. And shareholders need to reject the existing Board at the next annual meeting.
  • M
    3 day rule.. I am a buyer at 17.50 if it hits that number before 3 days. If not I will buy on Thursday. I dodged a pretty big bullet today. I had 2k at 25 and sold at 34. Whew!
  • A
    And there it is: Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer
    SALT LAKE CITY, June 27, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that.
    SALT LAKE CITY, June 27, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that.
  • W
    Anyone have any insight on what's going on here? Quarterly seemed pretty good YOY.
  • K
    What's happening to MYGN today is what's in store for most stocks if Warren elected.
  • v
    Not sure if Goldman realizes MYGN is now the only FDA approved for BRAC. See you later fly by night labs. You need Myriad’s data base to make accurate decisions. Who wants efficacy rates of 40-60%. This is a live and death decision. Who doesn’t like 99% accuracy!
  • A
    Am I understanding the situation correctly? After having perused the cc transcript, it's clear that they have known for months that existing revenue and income guidance would be wildly off. If true, why wasn't a warning issued in a more timely way?? It certainly seems to raise questions about management's ability to stay on top of, and/or communicate, the need for adjustments caused by reduced revenue accrual rates.
  • D
    Myriad announced today that UnitedHealthcare has issued a positive coverage decision for pharmacogenetic testing for multi-gene panels including the company’s GeneSight Psychotropic test. The coverage is for patients that have a diagnosis of major depressive disorder or anxiety and have failed at least one prior medication to treat their condition. The positive coverage decision is referenced in the UnitedHealthcare August 2019 Network Bulletin.
  • A
    I see we have a few profit-takers in the pre-market. It is my sincerest hope they regret doing that as others pile onto the good news from both Tuesday and today.
  • M
    I think I may have a good chance to buy it at $19.50. It may go lower, but I want to take a risk at this price and I plan to average down if it continues falling. It's a good gambling for me.
  • 1
    Anyone with any news or info on volume and price action? I’m thinking leaked news on fda resolution on genetics testing?
  • b
    Is 30% drop warranted after 10% drop in revenue and 20% miss on ER. WHo knows we will see tomorrow!

    Not worth shorting at this point!!!

    Roll the dice please!

    GLTA in stock casino!
  • C
    FYI: they gave the new CEO 1.3MM shares as part of his hiring package. must be nice. at $13.38 (702,888) and $12.33 (597,908).
  • R
    Earnings and guidance were great!! An outstanding buy right now!!